Medscape Medical NewsAll articles

AI-ECG Platform

Shenzhen Carewell Electronics., Ltd • Cardiovascular • 11/19/2018

510(k)IEC 62304 Class C
FDA Summary PDF

Device Purpose

The AI-ECG Platform is a software tool utilizing an AI algorithm to assist physicians in analyzing 12-lead resting ECGs for common cardiac abnormalities. It aims to enhance diagnostic efficiency by providing automated measurements and interpretations as an advisory aid, which clinicians can then review, edit, and confirm within a distributed system that manages ECG data from acquisition to reporting.

Summary

The AI-ECG Platform is a software system designed to assist qualified healthcare professionals in hospitals and other healthcare facilities with the measurement and interpretation of 12-lead resting ECGs. Its primary function is to aid in the assessment of common cardiac abnormalities, such as arrhythmias, myocardial infarction, ventricular hypertrophy, and abnormal ST-T changes, for the general adult population. The platform's interpretations are intended as an advisory tool, to be used alongside a physician's own expertise and knowledge of ECG analysis, and are not meant to be the sole basis for diagnosis. The system utilizes a Carewell ECG Measurement Algorithm combined with a Carewell ECG AI algorithm to automatically analyze ECG data received from compatible devices or via manual upload. Supported data formats include Carewell ECG, HL7 aECG, DICOM ECG, SCP ECG, and MFER ECG. ECG data is processed on a server, with results (measurements, interpretations, waveforms) downloaded to a physician’s client application for review, editing, confirmation, and report generation. Original waveform data is stored securely and permanently. The platform is not intended for patient monitoring, use with non-standard leads, or ECG signals collected without conductive paste/gel/fluid.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

AI-ECG Platform12-lead resting ECGECG interpretationArtificial Intelligence (AI) algorithmCardiac abnormalitiesArrhythmia detectionMyocardial infarction assessmentClinical decision supportECG data managementProgrammable diagnostic computer

Device Metadata

Submission Number
K180432
Company
Shenzhen Carewell Electronics., Ltd
Panel
Cardiovascular
Product Code
N/A
Data Type
Signals
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
detection/diagnosis

Relevant Clinical Questions

  • Q1. What is the validated diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of the AI algorithm for specific cardiac abnormalities like myocardial infarction or various arrhythmias compared to expert cardiologist consensus?; How does the AI-ECG Platform's performance vary across different patient demographics (e.g., age, sex, co-morbidities) or in the presence of complex ECG findings?; What specific features of the AI algorithm differentiate it from other ECG analysis algorithms, and what types of ECG patterns does it particularly excel or struggle with?; What is the typical workflow integration time and learning curve for physicians adopting the AI-ECG Platform, and how does it impact overall diagnostic efficiency in a clinical setting?; What are the data security and interoperability protocols for integrating the AI-ECG Platform with existing hospital EHR systems, particularly concerning the permanent storage of original ECG waveform data?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score45/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment✓ Detected in Summary
Postmarket Plan✓ Detected in Summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(algorithm)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials(server, platform)
✓ Detected
HBOMHardware Bill of Materials
- Not detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials
- Not detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
AI-ECG Platform - Shenzhen Carewell Electronics., Ltd | ESL FDA AI Device Intelligence